Aug 24 (Reuters) - Oculus Innovative Sciences Inc
* Got new 510(k) clearance from u.s. Fda for company’s new post-dermal-procedures product
* Co’s dermatology division, intraderm, will begin marketing post-dermal-procedures product in us beginning march 2017 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.